MX2009007038A - Derivados de mononitrato de isosorbida para el tratamiento de trastornos intestinales. - Google Patents

Derivados de mononitrato de isosorbida para el tratamiento de trastornos intestinales.

Info

Publication number
MX2009007038A
MX2009007038A MX2009007038A MX2009007038A MX2009007038A MX 2009007038 A MX2009007038 A MX 2009007038A MX 2009007038 A MX2009007038 A MX 2009007038A MX 2009007038 A MX2009007038 A MX 2009007038A MX 2009007038 A MX2009007038 A MX 2009007038A
Authority
MX
Mexico
Prior art keywords
treatment
intestinal disorders
isosorbide mononitrate
mononitrate derivatives
derivatives
Prior art date
Application number
MX2009007038A
Other languages
English (en)
Spanish (es)
Inventor
Marisabel Mourelle Mancini
Francisco Pubill Coy
Jose Repolles Moliner
Original Assignee
Lacer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38043051&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009007038(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lacer Sa filed Critical Lacer Sa
Publication of MX2009007038A publication Critical patent/MX2009007038A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2009007038A 2006-12-28 2007-12-27 Derivados de mononitrato de isosorbida para el tratamiento de trastornos intestinales. MX2009007038A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06380338A EP1941876A1 (en) 2006-12-28 2006-12-28 Isosorbide mononitrate derivatives for the treatment of Inflammation and ocular hypertension
PCT/EP2007/064591 WO2008080955A1 (en) 2006-12-28 2007-12-27 Isosorbide mononitrate derivatives for the treatment of intestinal disorders

Publications (1)

Publication Number Publication Date
MX2009007038A true MX2009007038A (es) 2009-08-25

Family

ID=38043051

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2009007038A MX2009007038A (es) 2006-12-28 2007-12-27 Derivados de mononitrato de isosorbida para el tratamiento de trastornos intestinales.
MX2009007040A MX2009007040A (es) 2006-12-28 2007-12-27 Derivados de mononitrato de isosorbida para el tratamiento de hipertension ocular.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2009007040A MX2009007040A (es) 2006-12-28 2007-12-27 Derivados de mononitrato de isosorbida para el tratamiento de hipertension ocular.

Country Status (21)

Country Link
US (1) US20080161389A1 (OSRAM)
EP (3) EP1941876A1 (OSRAM)
JP (2) JP2010514734A (OSRAM)
KR (2) KR20090112673A (OSRAM)
CN (2) CN101600425A (OSRAM)
AR (1) AR064543A1 (OSRAM)
AT (2) ATE484279T1 (OSRAM)
AU (2) AU2007341289B2 (OSRAM)
BR (2) BRPI0720663A2 (OSRAM)
CA (2) CA2674550A1 (OSRAM)
CL (2) CL2007003837A1 (OSRAM)
DE (2) DE602007009877D1 (OSRAM)
ES (3) ES2324130B1 (OSRAM)
IL (2) IL198912A0 (OSRAM)
MX (2) MX2009007038A (OSRAM)
NO (2) NO20092764L (OSRAM)
PL (2) PL2124930T3 (OSRAM)
RU (2) RU2009128970A (OSRAM)
UY (1) UY30847A1 (OSRAM)
WO (2) WO2008080939A1 (OSRAM)
ZA (2) ZA200903566B (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2149576A1 (en) * 2008-07-22 2010-02-03 Lacer, S.A. Isosorbide Nitrates having vasodilating activity
EP2149577B1 (en) * 2008-07-22 2011-04-27 Lacer, S.A. New stereospecific method for the preparation of dioxa-bicyclooctane compounds
EP2177216A1 (en) * 2008-10-13 2010-04-21 Lacer, S.A. Use of dianhydrohexite mononitrate derivatives as healing agents
WO2010055138A1 (en) * 2008-11-14 2010-05-20 Lacer, S.A. New stereospecific method for the preparation of dioxa-bicyclooctane compounds
EP2199294A1 (en) * 2008-12-19 2010-06-23 Lacer, S.A. New stereospecific method for the preparation of dioxa bicyclooctane nitrate compounds
EP2515899B1 (en) * 2009-12-23 2016-05-25 ARCA biopharma, Inc. Methods and compositions for cardiovascular diseases and conditions
HK1217323A1 (zh) * 2013-03-05 2017-01-06 阿彻丹尼尔斯米德兰德公司 异己糖醇单三氟甲磺酸酯及其合成方法
WO2018224419A1 (en) 2017-06-06 2018-12-13 Nicox S.A. Nitric oxide donating isomannide derivatives

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2739689C2 (de) * 1977-09-02 1986-10-16 Euratom Thermische Wärmepumpe
JPS60149521A (ja) * 1984-01-18 1985-08-07 Eisai Co Ltd 高眼圧・緑内障治療・予防用点眼剤
US5573758A (en) * 1995-04-28 1996-11-12 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers
US5925342A (en) * 1996-11-13 1999-07-20 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers
GB9720797D0 (en) * 1997-09-30 1997-12-03 Rhodes John Pharmaceutical composition for the treatment of inflammatory bowel disease and irritable bowel syndrome
ES2142773B1 (es) * 1998-10-07 2001-01-01 Lacer Sa Derivados de mononitrato de isosorbida y su empleo como agentes vasodilatadores con tolerancia desminuida.
JP2004517940A (ja) * 2001-01-31 2004-06-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング ピラゾロ[4,3−d]ピリミジンおよびニトレートまたはチエノピリミジンおよびニトレートを含む医薬製剤
WO2003079997A2 (en) * 2002-03-21 2003-10-02 Cayman Chemical Company Prostaglandin f2 alpha analogs in combinaiotn with antimicrobials for treating glaucoma
CN1863905A (zh) * 2003-09-08 2006-11-15 得克萨斯系统大学董事会 通过用前列腺素或前列腺素类似物补充培养基加强体外胚发育的方法以及组合物
ES2258365B1 (es) * 2003-10-03 2007-12-01 Lacer, S.A. Derivados de disulfuro, sulfuro, sulfoxido y sulfona de azucares ciclicos y sus usos.

Also Published As

Publication number Publication date
EP2124930B1 (en) 2010-10-13
JP2010514733A (ja) 2010-05-06
US20080161389A1 (en) 2008-07-03
AU2007341218B2 (en) 2010-09-09
BRPI0720664A2 (pt) 2014-01-14
EP2124930A1 (en) 2009-12-02
CA2674550A1 (en) 2008-07-10
AU2007341218A1 (en) 2008-07-10
IL198941A0 (en) 2010-02-17
ES2324130A1 (es) 2009-07-30
NO20092763L (no) 2009-07-27
AR064543A1 (es) 2009-04-08
CL2007003836A1 (es) 2008-07-11
AU2007341289B2 (en) 2010-08-26
ES2324130B1 (es) 2010-03-22
CL2007003837A1 (es) 2008-07-11
CN101600426A (zh) 2009-12-09
PL2114398T3 (pl) 2010-11-30
IL198912A0 (en) 2010-02-17
EP2114398A1 (en) 2009-11-11
WO2008080955A1 (en) 2008-07-10
KR20100100584A (ko) 2010-09-15
AU2007341289A1 (en) 2008-07-10
EP1941876A1 (en) 2008-07-09
PL2124930T3 (pl) 2011-04-29
NO20092764L (no) 2009-07-27
ZA200903566B (en) 2010-08-25
RU2009128968A (ru) 2011-02-10
KR20090112673A (ko) 2009-10-28
CA2674144A1 (en) 2008-07-10
EP2114398B1 (en) 2010-06-30
UY30847A1 (es) 2008-05-31
ATE472324T1 (de) 2010-07-15
CN101600425A (zh) 2009-12-09
RU2009128970A (ru) 2011-02-10
WO2008080939A1 (en) 2008-07-10
JP2010514734A (ja) 2010-05-06
BRPI0720663A2 (pt) 2014-01-14
ES2354317T3 (es) 2011-03-14
ATE484279T1 (de) 2010-10-15
ES2348314T3 (es) 2010-12-02
DE602007009877D1 (de) 2010-11-25
CN101600426B (zh) 2012-07-25
DE602007007523D1 (de) 2010-08-12
ZA200903567B (en) 2010-08-25
MX2009007040A (es) 2009-08-25

Similar Documents

Publication Publication Date Title
WO2008020040A3 (en) 2,5-dihydroxybenzene compounds for the treatment of fibrosis
WO2007138472A3 (en) Triazolopyridazine derivatives
WO2008046087A3 (en) Spiro compounds and their uses as therapeutic agents
UA92000C2 (en) 1-benzylindole-2-carboxamide derivatives
WO2010136474A3 (en) Substituted aminobutyric derivatives as neprilysin inhibitors
MX2009003874A (es) Derivados de espiro-oxindol triciclicos y sus usos como agentes terapeuticos.
WO2006067445A3 (en) Csf-1r kinase inhibitors
WO2009155121A3 (en) Inhibitors of pi3 kinase
WO2006011050A3 (en) Pyridine derivatives
MY143565A (en) Novel fluorocglycoside derivatives of pyrazoles: medicaments containing these compounds, and the use thereof
TW200728307A (en) Novel spirochromanone derivatives
MX2009007038A (es) Derivados de mononitrato de isosorbida para el tratamiento de trastornos intestinales.
SG147450A1 (en) Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
MY135218A (en) 2,6-quinolinyl and 2,6-naphthyl derivatives and their use in the treatment of vla-4 dependent diseases
WO2009013348A3 (en) Pyrimidine derivatives useful for the treatment of inflammatory or allergic conditions
WO2005115470A3 (fr) COMPOSITIONS PHARMACEUTIQUES CONTENANT DES DERIVES DE β-­CARBOLINE, ET LEUR UTILISATION POUR LE TRAITEMENT DES CANCERS
TW200722081A (en) New therapeutic combinations for the treatment or prevention of depression
PL1682528T3 (pl) Pochodne benzo[b][1,4]dioksepiny
TW200626158A (en) Naphthaline derivatives
WO2007146856A3 (en) Substituted gamma lactams as therapeutic agents
WO2007111983A3 (en) New therapeutic combinations for the treatment or prevention of psychotic disorders
WO2007138112A3 (en) Compounds that interact with ion channels, in particular with ion channels from the kv family
WO2006077024A3 (en) 5-aminoindole derivatives
MX2009005242A (es) Derivados de 3-(hetero)arilisoquinolinamida sustituida en posición 5, 6 o 7 y uso terapeutico del mismo.

Legal Events

Date Code Title Description
FG Grant or registration